{"id":"NCT00803244","sponsor":"Stallergenes Greer","briefTitle":"Safety and Efficacy on Phase III Study on 300 IR SLIT to Patients Suffering From Grass Pollen Rhinoconjunctivitis","officialTitle":"A Randomised, Double-blind, Placebo-controlled, Multi National, Phase III Study of the Efficacy and Safety of 300 IR Sublingual Immunotherapy (SLIT) Tablet, Starting 2 Months Before the Grass Pollen Season Once Daily to Patients Suffering From Grass Pollen Rhinoconjunctivitis","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2009-01","primaryCompletion":"2009-08","completion":"2010-01","firstPosted":"2008-12-05","resultsPosted":"2016-05-25","lastUpdate":"2016-05-25"},"enrollment":381,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"QUADRUPLE","primaryPurpose":"TREATMENT"},"conditions":["Primary Disease"],"interventions":[{"type":"DRUG","name":"300 IR","otherNames":["Sublingual immunotherapy tablet"]},{"type":"DRUG","name":"Placebo","otherNames":["Sublingual placebo tablet"]}],"arms":[{"label":"300 IR","type":"EXPERIMENTAL"},{"label":"Placebo","type":"PLACEBO_COMPARATOR"}],"summary":"The purpose of this study is to evaluate the efficacy and safety of sublingual tablets of grass pollen allergen extract when initiated 2 months before the grass pollen season compared with placebo for reduction of rhinoconjunctivitis symptoms and rescue medication usage.","primaryOutcome":{"measure":"Average Adjusted Symptom Score (AAdSS)","timeFrame":"Pollen period (average of 32.1 days)","effectByArm":[{"arm":"300 IR","deltaMin":5.58,"sd":0.33},{"arm":"Placebo","deltaMin":6.07,"sd":0.335}],"pValues":[{"comp":"OG000 vs OG001","p":"0.2344"}]},"eligibility":{"minAge":"12 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":null,"exclusionCount":null},"locations":{"siteCount":6,"countries":["France","Italy","Spain"]},"refs":{"pmids":[],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":1,"n":188},"commonTop":["ORAL PRURITUS","HEADACHE","THROAT IRRITATION","COUGH","ASTHMA"]}}